LSTA

#4423
Lisata Therapeutics, Inc. Common Stock
4.53 USD
-9.22%
セクター: ヘルスケア
ベース: USD
利益通貨: USD
日中レンジ
4.53
4.53
1年のレンジ
1.81
5.06
1日の変化
-9.22%
月次変化
-10.12%
6か月変化
+92.77%
1年の変化
+126.50%
以前の終値
4.99
始値
4.53
Bid
Ask
安値
4.53
High
4.53
ボリューム
2
チャート全体を表示

Financials

概要 明細書 統計
期次 年次
  • Market Capitalization 40.92 M
  • Employee 21
  • Founded 1980
  • CEO N/A
  • Website www.lisata.com
  • Headquarter Delaware, United States
  • FIGI BBG000BNVDR4
  • Industry Technology
総売上高
当期純利益
1株当たり基本利益（基本EPS）
有利子負債合計
フリーキャッシュフロー
現金および現金同等物
株価収益率
-0.97
売上高対価格比率
95.05

Lisata Therapeutics Inc

Lisata Therapeutics is an American clinical stage pharmaceutical company active in the field of oncology, specifically aimed at developing and commercializing new cancer therapies. It was formed through a merger of Cend Therapeutics and Caladrius Biosciences in September 2022. In 2019, the FDA granted their product, certepetide, orphan drug status in pancreatic cancer, followed by a Fast track status in 2022. Non-clinical data collected by Lisata and others have demonstrated enhanced delivery of various existing and emerging anti-cancer therapies, including chemotherapies, immunotherapies and RNA-based therapeutics when used with certepetide.

ニュース